Japan approves GSK's bronchitis and emphysema drug
The Japanese government has approved GlaxoSmithKilne and Nasdaq-listed Innoviva’s drug which treats chronic bronchitis and pulmonary emphysema.
FTSE 100
8,281.66
11:10 24/09/24
FTSE 350
4,568.98
11:10 24/09/24
FTSE All-Share
4,525.21
11:10 24/09/24
GSK
1,518.00p
11:09 24/09/24
Pharmaceuticals & Biotechnology
22,034.93
11:09 24/09/24
Japan’s Ministry of Health, Labour and Welfare approved the use of Relvar, which relieves symptoms of chronic obstructive pulmonary diseases, for a dose of 100/25mcg a day using the Ellipta dry powder inhaler.
Relvar Ellipta is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting beta two agonist, vilanterol, which has been used in Japan to treat asthma since 2013.
Eric Dube, senior vice president and head of GSK’s global respiratory franchise, said, "We are delighted with this approval of Relvar Ellipta, our third chronic obstructive pulmonary disease treatment to gain marketing authorisation in Japan in under three years, and believe it will be an important new option for appropriate patients with COPD, as well as those with asthma.”
Mike Aguiar, chief executive of Innoviva, added: "The approval of Relvar Ellipta for Chronic obstructive pulmonary disease will provide Japanese physicians with a new, important once-daily, inhaled treatment option for appropriate patients. This represents yet another significant milestone in the respiratory partnership between Innoviva and GSK."